Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy

Evgeny V. Fominskiy, Anna Mara Scandroglio, Giacomo Monti, Maria Grazia Calabrò, Giovanni Landoni, Antonio Dell'Acqua, Luigi Beretta, Elena Moizo, Alfredo Ravizza, Fabrizio Monaco, Corrado Campochiaro, Marina Pieri, Maria Luisa Azzolini, Giovanni Borghi, Martina Crivellari, Caterina Conte, Cristina Mattioli, Paolo Silvani, Milena Mucci, Stefano TuriStefano Tentori, Martina Baiardo Redaelli, Marianna Sartorelli, Piera Angelillo, Alessandro Belletti, Pasquale Nardelli, Francesco Giuseppe Nisi, Gabriele Valsecchi, Cristina Barberio, Fabio Ciceri, Ary Serpa Neto, Lorenzo Dagna, Rinaldo Bellomo, Alberto Zangrillo, for the COVID-BioB Study Group

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Background: There is no information on acute kidney injury (AKI) and continuous renal replacement therapy (CRRT) among invasively ventilated coronavirus disease 2019 (COVID-19) patients in Western healthcare systems. Objective: To study the prevalence, characteristics, risk factors and outcome of AKI and CRRT among invasively ventilated COVID-19 patients. Methods: Observational study in a tertiary care hospital in Milan, Italy. Results: Among 99 patients, 72 (75.0%) developed AKI and 17 (17.7%) received CRRT. Most of the patients developed stage 1 AKI (33 [45.8%]), while 15 (20.8%) developed stage 2 AKI and 24 (33.4%) a stage 3 AKI. Patients who developed AKI or needed CRRT at latest follow-up were older, and among CRRT treated patients a greater proportion had preexisting CKD. Hospital mortality was 38.9% for AKI and 52.9% for CRRT patients. Conclusions: Among invasively ventilated COVID-19 patients, AKI is very common and CRRT use is common. Both carry a high risk of in-hospital mortality.

Original languageEnglish
Number of pages8
JournalBlood Purification
DOIs
Publication statusAccepted/In press - 13 Jul 2020

Cite this